|
Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency |
Institute of Health Economics |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute of Health Economics. Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency. Edmonton: Institute of Health Economics (IHE). 2016 Authors' objectives This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting. Indexing Status Subject indexing assigned by CRD MeSH Galactosemias; Hemoglobin C Disease; Hemoglobin SC Disease; Homocystinuria; Humans; Infant, Newborn; Neonatal Screening; Severe Combined Immunodeficiency; beta-Thalassemia Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Institute of Health Economics (IHE), #1200, 10405 Jasper Avenue, Edmonton, AB T5J 3N4, Canada Email: info@ihe.ca AccessionNumber 32016001098 Date abstract record published 16/11/2016 |
|
|
|